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Aim: Radiopeptide therapy with beta emitter labeled 177Lu/90Y- DOTA(0)-Phe(1)-Tyr(3)-octreotide (DOTATOC) and more recently 
also alpha emitting 213Bi-DOTATOC are promising new treatments for neuroendocrine tumors. No early predictors for treatment 
response have been recognized and tumor-shrinkage after radiation therapy appears slowly. In some solid tumors a decline in tumor 
perfusion was found predictive of final treatment response but the gold standard multiphase computed tomography (CT) has a high 
radiation burden. Therefore we evaluated the ability of contrast-enhanced ultrasound (CEUS) to evaluate tumor perfusion as a response 
criteria.  Materials and Methods: 14 patients with hepatic neuroendocrine tumor (NET) metastases were enrolled in the retrospective 
study. Eleven patients were treated with beta-emitting 177Lu/90Y-DOTATOC, either intravenous (i.v.) (n = 5) or intra-arterial (i.a.) 
(n = 6) and three patients received alpha-emitting 213Bi-DOTATOC (i.a.). CEUS and contrast-enhanced CT (CE-CT) were performed 
before and 3 months after treatment. Results: CE-CT and CEUS presented comparable results in the baseline study and in the assess-
ment of perfusion changes due to the different treatment regimes. A therapy related decrease in tumor perfusion is an early predictor 
of longterm morphologic response.  Conclusion:  CEUS is available and radiation free technique which showed comparable results for 
perfusion and diameter of liver metastases compared to CE-CT. Intensity reduction in an arterial phase CEUS can be seen as a pos-
itive sign indicating long term tumor response to treatment. Therefore CEUS may be considered as an imaging modality for monitor-
ing early treatment after focal alpha and beta targeted therapy.
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Liver metastases are often the life-limiting factors for 
patients with gastroenteropancreatic neuroendocrine 
tumors (GEP-NET). Most GEP-NETs, as well as their liver 
metastases are highly vascularised with a dense intra-
mural vascular network [1]. Hence they show the typical 
peripheral contrast enhancement in the arterial phase 
of contrast-enhanced computed tomography (CE-CT) 
and contrast-enhanced ultrasound (CEUS). Moreover, 
they demonstrate an increased somatostatin receptor 
expression both in primary and metastatic lesions.
Concerning therapeutic and diagnostic options, the 
PET tracer DOTA(0)-Phe(1)-Tyr(3)-octreotide (DOTA-
TOC), a 68Ga-labelled somatostatin analog, has been 
shown to have high sensitivity and specificity for GEP-NET 
detection and staging [2]. Treatment with 90Y- or 177Lu-
DOTATOC (beta emitters) is emerging as a potent therapy 
in patients with GEP-NETs. Systemic (i.v.) treatment can 
induce partial remission in 25–30% of the patients [3]. 
Tumor uptake of DOTATOC can be enhanced by loco-
regional (i.a.) administration [4]; however, only patients 
with limited tumor extent are eligible for this approach. 
In comparison to beta emitters, alpha emitters have 
a higher linear energy transfer and potentially can induce 
tumor necrosis by structural damage of the targeted cell 
rather than radiation-induced apoptosis as occurred with 
beta irradiation.
Monitoring structural and functional characterisation 
of a tumor during therapy is important to tailor individual 
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patient care and evaluate novel treatment approaches. 
Since shrinkage of liver metastases — even with effec-
tive therapy — is rarely observed, modified response 
criteria, based on the degree of contrast enhancement, 
have been suggested by the American Association for 
the Study of Liver diseases (AASLD) and the European 
Association for the study of the liver (EASL) (modified 
Response Evaluation Criteria in Solid Tumors (mRE-
CIST)). However, multi-phase CE-CT is associated 
with high radiation exposure. We investigated the role 
of CEUS to detect changes in perfusion as a non-
invasive indicator of therapy response.
MATERIALS AND METHODS
Study design.14 patients with hepatic NET me-
tastases that have been treated with beta-emitting 
177Lu/90Y-DOTATOC, either i.v. (n = 5) or i.a. (n = 6) 
or alpha-emitting 213Bi-DOTATOC i.a. (n = 3). 
According to the Society of Nuclear Medicine (SNM) 
and European Association of Nuclear Medicine (EANM) 
guideline all patients prior to peptide guided radiorecep-
tor therapy (PRRT) underwent a Somatostatin receptor 
(subtype 2 and 5) imaging procedure (68Ga-DOTATOC 
or Octreotid-Scan) to elaborate the receptor expression. 
Patients who underwent surgery of the primary tumor (for 
example pancreatic cancer) and afterwards predomi-
nantly had their tumor load in the liver underwent loco-
regional therapeutic treatment regime (i.a. DOTATOC-
Therapy). In contrast, patients who presented at the first 
imaging time point (68Ga-DOTATOC or Ocretotid-Scan) 
with an extensive systemic tumor spread underwent the 
systemic PRRT approach (i.v. DOTATOC-Therapy). 
CEUS and CE-CT were performed as part of our 
clinical standard procedures and within the approved 
indications before and 3 months after treatment. 
A retrospective analysis was done and was approved 
by the institutional review board (IRB). Written informed 
consent was obtained from all patients. No prospective 
experiments with human subjects were performed and 
the study was in accordance with the Helsinki Declara-
tion and our national regulations.
Contrast-enhanced ultrasound (CEUS). Prior 
to and 3 months after therapy, low-MI CEUS (FR = 19 fps, 
mechanical index MI = 0.15; HI VERSION Preirus, Hitachi, 
Switzerland) was performed. The examination was car-
ried out with an intermittent breath-holding technique. 
One target lesion was identified in each patient by con-
ventional ultrasound. Subsequently, dynamic imaging 
of these metastases was performed immediately after 
i.v. application of 2.4 cc of the contrast agent SonoVue® 
(Bracco S.P.A., Italy) with a duration of two minutes 
to monitor early arterial contrast enhancement and late 
portal-venous phase. The typical radiological feature 
of a liver metastasis of GEP-NETs was arterial phase 
hypervascularisation followed by portal-venous wash-
out. Using a self-developed analysis software, regions 
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Fig. 1. Systemic therapy with 4+4 GBq 90Y-/177Lu-DOTATOC. a, b. CEUS image (a) and corresponding time-intensity curve (b) of a neu-
roendocrine metastasis and normal liver parenchyma before therapy. c, d. CEUS image (c) and corresponding time-intensity curve (d) 
of a neuroendocrine metastasis and normal liver parenchyma 3 months after systemic therapy with 4+4 GBq 90Y-/177Lu-DOTATOC. White 
arrows indicate metastatic lesion. Undulations in curves are caused by breathing artefacts. An increased uptake in the arterial phase after 
therapy (d) was associated with tumor progression in the follow-up. Met — metastasis; Norm — Normal liver parenchyma
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of interest (ROI) were marked in the liver metastases 
and in adjacent normal liver parenchyma, measuring 
change in intensity over time. Peak image intensity and 
time to peak were recorded for each ROI.
Contrast-enhanced computed tomography (CE-
CT). Prior to and 3 months after therapy, contrast-en-
hanced CT was performed in each patient using a Siemens 
Biograph 6 Positron Emission Tomography/Computed 
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Fig. 2. Intra-arterial therapy with 4+4 GBq 90Y-/177Lu-DOTATOC. a, b. CEUS (a) and corresponding time-intensity curves (b) of a neu-
roendocrine metastasis and normal liver parenchyma prior to therapy. c, d. CEUS (c) and corresponding time-intensity curves (d) 
of a neuroendocrine metastasis and normal liver parenchyma 3 months after i.a. therapy with 4+4 GBq 90Y-/177Lu-DOTATOC. White 
arrows indicate metastatic lesion. A decline in tumor contrast enhancement was observed in CEUS (a, c) and equal to multi-phase 
CT (b, d) and was associated with tumor shrinkage in the long term follow-up. Met — metastasis; Norm — Normal liver parenchyma.
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Fig. 3. Intra-arterial therapy with 4+2 GBq 90Y-/177Lu DOTATOC. a, b. CEUS (a) and corresponding time-intensity curves (b) of a neu-
roendocrine metastasis and normal liver parenchyma before therapy. d, e. CEUS (d) and corresponding time-intensity curves (e) 
of a neuroendocrine metastasis and normal liver parenchyma 3 months after i.a. therapy. c, f. Sequential hybrid imaging of 68Ga-
DOTATOC PET/CT before (c) and after (f) i.a. therapy also confirm CEUS finding. Met — metastasis; Norm — Normal liver parenchyma
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Tomography (PET/CT). A ROI of 40 pixels was marked 
in the center and outer rim of each evaluated metastatic 
lesion in the arterial phase of the CE-CT. The ratio of inten-
sity of lesions and normal liver parenchyma was recorded 
measuring corresponding Hounsfield units (HU).
DOTATOC positron emission tomography (DOTA-
TOC PET). DOTATOC-PET/CT was also performed on the 
Biograph 6 (Siemens, Knoxville, USA). Imaging was initi-
ated about 45 min after i.v. injection of 89–189 MBq 68Ga-
DOTATOC. Static emission scans, corrected for dead 
time, scatter and decay were acquired from the vertex 
to the proximal legs — requiring eight bed positions, 4 min 
each. The low-dose CT without contrast agent was used 
for attenuation correction. The images were iteratively 
reconstructed with the OSEM (ordered subset expecta-
tion maximisation) algorithm using four iterations with 
eight subsets and Gaussian filtering to achieve an in-plane 
spatial resolution of 5 mm at full-width half-maximum. 
RESULTS
Prior to therapeutic intervention, all liver metas-
tases demonstrated marked enhancement on both 
CE-CT and CEUS in all three treatment groups.
For the i.v. group (beta radiation) a significant de-
cline of enhancement was observed in 1/5 patients 
3 months after intervention. In 3/5 patients no change 
in enhancement was seen and in one patient (Fig. 1) 
the lesion progressed.
For the i.a. group (beta radiation) 3/6 patients 
demonstrated both a decline of tumor vascularity 
as assessed with CEUS and of diameter as assessed 
with arterial phase CT (Fig. 2) and also a decline 
in SSR2 expression in DOTATOC PET imaging (Fig. 3).
For the i.a. group, treated with 213Bi-DOTATOC 
(alpha radiation), CEUS and arterial phase CT demon-
strated a decrease of tumor perfusion (Fig. 4). 
Regarding contrast intensity in CEUS in the i.a. group 
treated with 213Bi-DOTATOC (relative values), metastases 
had a 40% higher contrast intensity than normal liver 
parenchyma with an early onset of contrast enhance-
ment before treatment (metastatic liver parenchyma set 
as 100% with an early onset of contrast enhancement; 
intensity in normal liver parenchyma was measured 60% 
of metastatic liver parenchyma (Fig. 4 b)) to almost equi-
librium 3 months after therapy (normal liver parenchyma 
and metastases reached the same level of intensity while 
metastases still showed an earlier contrast enhancement 
than normal liver parenchyma (Fig 4 d)). In CE-CT (ab-
solute values), measuring Hounsfield units in peripheral 
regions of metastases, i.a. application of 213Bi-DOTATOC 
led to a 50% decrease of density values within 3 months 
(800 HU before treatment, 400 HU 3 months later (Fig. 4 b, 
d). Simultaneously, i.a. application of 213Bi-DOTATOC 
did not lead to a significant shrinkage of metastases 
within 3 months. Nevertheless, in the longterm follow up 
(9 months) none of these lesions progressed.
The absence of intensity reduction in an arterial 
phase CEUS can be seen as a negative sign indicating 
unresponsiveness to treatment.
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Fig. 4. Intra-arterial therapy with 213Bi-DOTATOC. a, b. CEUS (a) and corresponding time-intensity curves (b) of a neuroendocrine 
metastasis and normal liver parenchyma before therapy. c, d. CEUS (c) and corresponding time-intensity curves (d) of a neuroen-
docrine metastasis and normal liver parenchyma 3 months after i.a. therapy with 213Bi-DOTATOC. White arrows indicate metastatic 
lesion. Positive contrast in arterial and portal venous phase decline after therapy — this was similar in both CEUS and CT. Met — 
metastasis; Norm — Normal liver parenchyma
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DISCUSSION
As described abovem, patients with systemic 
tumor manifestations outside the liver underwent the 
systemic PRRT approach (i.v. DOTATOC-Therapy). 
Patients without tumor manifestations outside the liver 
underwent the loco-regional therapeutic treatment 
regime (i.a. DOTATOC-Therapy), irrespective of the 
size and number of liver metastases, according to the 
SNM- and EANM guidelines. 
In patients with liver-metastases from GEP-NETs 
i.a. treatment with 177Lu/90Y-DOTATOC lead to a sig-
nificant decrease of tumor vascularity and diameter, 
compared to treatment with systemic treatment. The 
observed response seen with targeted beta radiation 
administered either via i.v. or i.a. was in accordance 
with prior results. A decline in lesion perfusion cor-
related with tumor shrinkage on arterial phase CT 
[5]. In contrast, high energy alpha radiation produced 
marked reduction in tumor vascularity with little 
or no change in tumor diameter after several months. 
Thus, this data suggests that alpha irradiation leads 
to early changes in tumor microcirculation, occurring 
prior to tumor shrinkage.
Comparing CEUS and CE-CT, results of tumor 
perfusion and diameter were equal in both modalities, 
regardless of the therapy regimen. One important 
point to mention is that the first structural changes 
after PRRT are visible about six weeks after therapy 
in CEUS and CE-CT. However, morphological changes, 
which can be detected with CT and CEUS need at least 
a follow up period of 6 months to become visible. This 
coincides with findings from evaluations of unclear liver 
lesions, where contrast enhanced ultrasound was even 
more accurate than multisliced computed tomography 
in predicting malignancy and benignity [6]. This applies 
especially to lesions in the caudal and ventral parts 
of the liver, which can easily be visualized by ultra-
sound. Problems in the evaluation of subdiaphragmatic 
lesions are still unchanged, which is a limitation for the 
use of ultrasound for follow-up examinations in these 
liver segments. Under optimal ultrasound conditions, 
when the whole liver can be imaged, CEUS reaches 
a diagnostic certainty of > 90% and is as reliable 
as contrast-enhanced MRI, and beats CE-CT [7, 8]. 
Correspondingly high sensitivity rates of CEUS in liver 
tumors have been reported in many recent works [9].
A limiting factor of this study is the relatively small 
number of 14 patients that has been examined. That 
was due to the fact that not all of the patients with liver 
metastases of GEP-NETs in our hospital were available 
for a comparison of CEUS, CE-CT and DOTATOC-PET/
CT. In each patient we examined no more than one 
target lesion due to technical requirements in CEUS. 
In summary CEUS is a reliable method to monitor 
early changes in metastases even before true volume 
shrinkage occurs. After focal alpha targeted therapy 
results in CEUS were as valuable as in CE-CT, which 
is the common way of examining tumor response. 
CEUS is typically available at lower cost and without 
additional ionizing radiation compared to CT, and 
it is portable. It increases individual patient care and 
reduces costs. Therefore, CEUS may be considered 
as an additional imaging modality to assess the early 
mircovascular tumor environment in follow-up studies 
after focal alpha targeted therapy.
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